Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep 27:2:102-5.
doi: 10.2174/1874440000802010102.

Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease

K Reetz  1 , H R Siebner, C Gaser, J Hagenah, C Buechel, M Kasten, D Petersen, P P Pramstaller, C Klein, F Binkofksi
Affiliations

Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease

K Reetz et al. Open Neuroimag J. .

Abstract

In the present voxel-based morphometric study, we investigated whether the severity and duration of disease are associated with alterations in gray matter volume (GMV) in symptomatic Parkin mutation carriers (sPARKIN-MC) and patients with idiopathic Parkinson's disease (iPD). Regression analyses revealed different negative correlations between GMV in cortical motor areas and the severity as well as the disease duration in sPARKIN-MC and iPD patients. SPARKIN-MC showed a less involvement of cortical motor areas, in particular in the supplementary motor area (SMA) than iPD patients. Specifically, in iPD patients, but not in sPARKIN-MC, there was a negative correlation between the SMA degeneration and the UPDRS-II item freezing. The different degeneration patterns may mirror diverse kinetics of the disease progress in these two groups of PD patients with different underlying etiologies.

Keywords: Parkin mutation carriers; Parkinson’s disease; supplemetary motor area; voxel-based morphometry..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Clinical correlation between the UPDRS-II freezing item in iPD patients.
See this image and copyright information in PMC

References

    1. Klein C, Schlossmacher MG. Parkinson disease genetics: Implications for neurological care. Nat Clin Neurol. 2006;2(3):136–46. - PubMed
    1. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol. 2003;54(2):176–85. - PubMed
    1. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain. 2004;127(Pt 4):791–800. - PubMed
    1. Hu MT, White SJ, Chaudhuri KR, et al. Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm. 2001;108(5):571–80. - PubMed
    1. Summerfield C, Junque C, Tolosa E, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol. 2005;62(2):281–5. - PubMed

LinkOut - more resources